secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001437749-23-015313
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 5.02, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Diffusion Pharmaceuticals CFO William Hornung departs; separation agreement provides $254K lump sum
--------------------------------------------------------------------------------

- CFO William K. Hornung departed effective May 15, 2023, after serving since September 2018.
- Separation benefits include lump-sum of $254,663 (9 months base salary) and pro-rated bonus of $44,014.
- Vested stock options remain exercisable for 3 months post-separation.
- Health insurance premium reimbursement of $25,388 provided for 12 months.
- No successor CFO named; CEO Robert J. Cobuzzi Jr. remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923015313/0001437749-23-015313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774923015313/dffn20230519_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-015313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer